Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elicio Therapeutics

http://www.elicio.com

Latest From Elicio Therapeutics

Finance Watch: Three New IPOs, But Three Hopefuls Hold Back

IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.

Financing Business Strategies

Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs

Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings. 

Financing Growth

Finance Watch: $2.2bn In New Funding Sources In February, So Far

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Financing Innovation

Novartis Snaps Up KRAS Inhibitor R&D

Novartis has taken an option on novel inhibitors of the KRAS cell signaling pathway while it funds the drug discovery research at the Cancer Research UK’s Beatson Institute.

Deals Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register